Literature DB >> 9632616

Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys.

B L Perlaza1, M Arévalo-Herrera, K Brahimi, G Quintero, J C Palomino, H Gras-Masse, A Tartar, P Druilhe, S Herrera.   

Abstract

Aotus lemurinus monkeys were immunized with pools of either lipid-tailed peptides injected in PBS or peptides in Montanide ISA-51, all derived from four Plasmodium falciparum pre-erythrocytic antigens, namely, LSA1, LSA3, SALSA, and STARP. These formulations were well tolerated. Their immunogenicity was demonstrated by the induction of both B- and T-cell responses to most of the peptides studied (of the 12, 10 induced antibody production, 9 induced T-cell proliferative responses, and all 12 induced gamma interferon secretion). Immune responses proved to be long lasting, since some were still detectable 210 days after immunization. Of particular importance is the fact that B- and T-cell responses elicited in this way by synthetic peptides were specific for native parasite proteins on P. falciparum sporozoites and liver stage parasites.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632616      PMCID: PMC108363     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Survival and antigenic profile of irradiated malarial sporozoites in infected liver cells.

Authors:  A Suhrbier; L A Winger; E Castellano; R E Sinden
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

2.  Protection against malaria induced by irradiated sporozoites.

Authors:  S Mellouk; F Lunel; M Sedegah; R L Beaudoin; P Druilhe
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

3.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.

Authors:  K Deres; H Schild; K H Wiesmüller; G Jung; H G Rammensee
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

4.  Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum.

Authors:  R Rodriguez; A Moreno; F Guzman; M Calvo; M E Patarroyo
Journal:  Am J Trop Med Hyg       Date:  1990-10       Impact factor: 2.345

5.  Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens.

Authors:  G H Campbell; A Moreno; M E Patarroyo; W E Collins
Journal:  Am J Trop Med Hyg       Date:  1990-10       Impact factor: 2.345

6.  T and B cell responses of Plasmodium falciparum malaria-immune individuals to synthetic peptides corresponding to sequences in different regions of the P. falciparum antigen Pf155/RESA.

Authors:  M Troye-Blomberg; E M Riley; H Perlmann; G Andersson; A Larsson; R W Snow; S J Allen; R A Houghten; O Olerup; B M Greenwood
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

7.  Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins.

Authors:  S Herrera; M A Herrera; B L Perlaza; Y Burki; P Caspers; H Döbeli; D Rotmann; U Certa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen.

Authors:  D A Fidock; V Pasquetto; H Gras; E Badell; W Eling; W R Ballou; J Belghiti; A Tartar; P Druilhe
Journal:  Eur J Immunol       Date:  1997-10       Impact factor: 5.532

9.  Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro.

Authors:  L Schofield; A Ferreira; R Altszuler; V Nussenzweig; R S Nussenzweig
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

10.  Immunization of owl monkeys with the ring-infected erythrocyte surface antigen of Plasmodium falciparum.

Authors:  W E Collins; R F Anders; T K Ruebush; D J Kemp; G C Woodrow; G H Campbell; G V Brown; D O Irving; N Goss; V K Filipski
Journal:  Am J Trop Med Hyg       Date:  1991-01       Impact factor: 2.345

View more
  8 in total

1.  Naturally acquired IgG antibodies against the C-terminal part of Plasmodium falciparum sporozoite threonine-asparagine-rich protein in a low endemic area.

Authors:  Chittakun Suwancharoen; Chaturong Putaporntip; Thanaporn Rungruang; Somchai Jongwutiwes
Journal:  Parasitol Res       Date:  2011-02-01       Impact factor: 2.289

Review 2.  Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design.

Authors:  Javier E Garcia; Alvaro Puentes; Manuel E Patarroyo
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

3.  DNA immunization by Plasmodium falciparum liver-stage antigen 3 induces protection against Plasmodium yoelii sporozoite challenge.

Authors:  J P Sauzet; B L Perlaza; K Brahimi; P Daubersies; P Druilhe
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.

Authors:  S Dutta; L A Ware; A Barbosa; C F Ockenhouse; D E Lanar
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

5.  Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides.

Authors:  Lbachir BenMohamed; Alan Thomas; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

6.  Liver stage antigen 3 Plasmodium falciparum peptides specifically interacting with HepG2 cells.

Authors:  Javier E García; Hernando Curtidor; Ramses López; Luis Rodríguez; Ricardo Vera; John Valbuena; Jaiver Rosas; Marisol Ocampo; Alvaro Puentes; Martha Forero; Manuel A Patarroyo; Manuel Elkin Patarroyo
Journal:  J Mol Med (Berl)       Date:  2004-08-07       Impact factor: 4.599

7.  Genetic immunisation by liver stage antigen 3 protects chimpanzees against malaria despite low immune responses.

Authors:  Pierre Daubersies; Benjamin Ollomo; Jean-Pierre Sauzet; Karima Brahimi; Blanca-Liliana Perlaza; Wijnand Eling; Hubert Moukana; Pierre Rouquet; Charles de Taisne; Pierre Druilhe
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

Review 8.  Nanotechnology in vaccine delivery.

Authors:  Laura J Peek; C Russell Middaugh; Cory Berkland
Journal:  Adv Drug Deliv Rev       Date:  2008-02-07       Impact factor: 15.470

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.